https://orcid.org/0000-0002-3422-1309
Figures & data
© 2023 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group
Figure 1. Study population selection from the Medicare FFS database. FFS, fee for service; MF, myelofibrosis.
Table 1. Patient demographics and clinical characteristics at MF diagnosis.
Table 2. HCRU of patients who filled and did not fill ≥1 prescription of ruxolitinib.
Figure 2. All-cause direct medical (a) and total health-care costs (b) PPPM. DME, durable medical equipment; ED, emergency department; PPPM, per patient per month; SNF, skilled nursing facility.
Figure 3. Survival outcomes. The reference for the HR was the cohort of patients who did not fill a ruxolitinib prescription. The HR was adjusted for age, sex, race, region, dual and LIS eligibility, CCI score, clinical conditions of interest (including PV, ET, hypertension, hyperlipidemia, diabetes, anemia, transfusion use), and all-cause total healthcare costs during the 12-month pre-index period. CCI, Charlson Comorbidity Index; ET, essential thrombocythemia; HR, hazard ratio; LIS, low-income subsidy; OS, overall survival; PV, polycythemia vera.
Data availability statement
The data described in this paper are sourced from Centers for Medicare and Medicaid Services (CMS) Medicare FFS claims and enrollment data. The analytic file constructed for this analysis cannot be shared due to restrictions set forth in the governing Data Use Agreement with CMS. Researchers may request use of CMS data through the Research Data Assistance Center.